Evidence map›Paper›PMID 35613189›Full record

ArticleArquivos brasileiros de cardiologia2022

Hormone therapy and Hypertension in Postmenopausal Women: Results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).

Luana Ferreira-Campos, Ligia Gabrielli, Maria da Conceição Chagas Almeida, Estela Maria Leão Aquino, Sheila Maria Alvim Matos, Rosane Harter Griep, Roque Aras

Open access · diamondAbstract read
In one paragraph

Article in Arquivos brasileiros de cardiologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Luana Ferreira-CamposUniversidade Federal da Bahia - Programa de Pós-graduação em Medicina e Saúde, Salvador, BA - Brasil.ORCID 0000-0001-8280-0412
Ligia GabrielliUniversidade Federal da Bahia - Instituto de Saúde Coletiva, Salvador, BA - Brasil.
Maria da Conceição Chagas AlmeidaFundação Oswaldo Cruz (Fiocruz) - Instituto Gonçalo Moniz, Salvador, BA - Brasil.
Estela Maria Leão AquinoUniversidade Federal da Bahia - Instituto de Saúde Coletiva, Salvador, BA - Brasil.
Sheila Maria Alvim MatosUniversidade Federal da Bahia - Instituto de Saúde Coletiva, Salvador, BA - Brasil.
Rosane Harter GriepFundação Oswaldo Cruz (Fiocruz) - Laboratório de Educação em Ambiente e Saúde, Rio de Janeiro, RJ - Brasil.
Roque ArasUniversidade Federal da Bahia Faculdade de Medicina da Bahia, Salvador, BA - Brasil.ORCID 0000-0002-2161-3696
Universidade Federal da Bahia · BRFundação Oswaldo Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertension is a major risk factor for cardiovascular morbidity and mortality in post-menopausal women. Although menopausal hormone therapy (MHT) is a very effective treatment for vasomotor symptoms during this period, the influence of this therapy on blood pressure is not yet clear.

objectiveTo evaluate the relationship between the use of MHT and hypertension in participants of the ELSA-Brasil.

methodsA cross-sectional study using the baseline ELSA-Brasil data in a cohort of 2,138 women who had experienced natural menopause. This study analyzed hypertension, defined as arterial pressure ≥140/90 mmHg or previous antihypertensive use, and use of MHT, with participants being classified into never, past, and current users. Associations were assessed using an adjusted logistic regression model, with statistical significance set at p<0.05.

resultsOverall, 1,492 women (69.8%) had never used MHT, 457 (21.4%) had used it in the past, and 189 (8.8%) were current users. The use of MHT was more common in women who had a body mass index (BMI) <25 kg/m2and triglyceride levels <150 mg/dl, and who were physically less inactive, non-smokers, and non-diabetics. Current MHT users were less likely to have hypertension (OR=0.59; 95% CI: 0.41-0.85) compared to those who had never used MHT. In most cases, MHT was started at or before 59 years of age, within 10 years of becoming menopausal, and its use lasted for up to five years.

conclusionCurrent MHT use was not related to hypertension, particularly in healthy women and in those under 60 years of age.

Indexed as

HypertensionPostmenopauseAdultBrazilChildCross-Sectional StudiesEstrogen Replacement TherapyFemaleHormone Replacement TherapyHormonesHumansLongitudinal StudiesMenopauseHormones

Identifiers

PMID35613189
PMCPMC9368886
OpenAlexW4280513399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.